Open Label Phase 2a, Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA, Part B)

Study type: Clinical Trials Posting date: 10/23/2023 Last updated: 04/16/2025 Status: Recruiting Phase: Phase 2a Country: United States Eligibility:

18 years to 75 years of age; diagnosed with severe alopecia areata

Drug: Bempikibart (ADX-914) Administration: subcutaneous injection Sponsor: Q32 Bio Sponsor Link: Click here ClinicalTrials.gov link: Click here Location: Multiple locations throughout the U.S.


Description:

Alopecia areata is an autoimmune disease resulting in hair loss that is usually in one or more coin-shaped patches on the face, scalp or other areas of the body that grow hair. We are recruiting participants between 18 and 75 years of age with severe alopecia areata (AA) to take part in an investigational study. The purpose of the study is to evaluate how effective injections of the investigational drug called bempikibart (ADX-914) are on reducing hair loss in patients with severe AA.

The study consists of receiving an injection under the skin with the investigational product ADX-914 once a week for 4 weeks (4 doses) and then every two weeks over a 32-week period (16 doses). After your 36-week treatment period, there will be a 16-week follow-up period to observe the findings. Your participation in the study may last up to 56 weeks, including a Screening Period of up to 30 days, 36 weeks of Study Treatment Period, and a Follow-Up Period of 16 weeks. You will have a total of 26 in-person visits throughout the study.

Study visits take approximately 1 to 2.5 hours each.

Blood samples will be collected from all participants at each visit.

Medical photography, and SALT assessment will be taken at screening, and weeks 1, 6, 12, 18, 24, 30, 36, 44 and 52. An electrocardiogram to check heart health will be taken at screening, and weeks 36 and 52.

Compensation for time and travel will be available. There will be no cost to you for taking part in this study. You will be provided with all study medication, examinations and medical care related to the study at no cost to you.

This study is taking place at multiple locations throughout the United States.

CTI (Clinical Trials Institute of Northwest Arkansas)
Fayetteville, Arkansas
Phone: 479-544-3483

California Dermatology & Clinical Research Institute
Encinitas, California
Phone: 619-787-5723

First OC Dermatology Research, Inc.
Fountain Valley, California
Phone: 714-531-2966

Dermatology Physicians of Connecticut
Fairfield, Connecticut
Phone: 203-675-9818

ForCare Clinical Research
Tampa, Florida
Phone:
813-264-2155

Equity Medical
Bowling Green, Kentucky
Phone: 270-213-7777

Lahey Hair Loss Center of Excellence
Burlington, Massachusetts
Phone: 781-744-1375

Bobby Buka MD, PC (The Dermatology Specialist)
New York, New York
Phone: 212-385-3700

Equity Medical
New York, New York
Phone: 212-466-6550

WDC Cosmetic and Research, PLLC
Wilmington, North Carolina
Phone: 910-256-4350

Bexley Dermatology Research
Bexley, Ohio
Phone: 614-725-5010

Dermatologists of Southwest Ohio
Mason, Ohio
Phone: 513-701-5526

Apex Clinical Research Center
Painesville, Ohio
Phone: 440-940-2739

Austin Institute for Clinical Research
Houston, Texas
Phone: 713-985-0210 ext 1164

Jordan Valley Dermatology Center
South Jordan, Utah
Phone: 801-316-0266

Dermatology Specialists of Spokane
Spokane, Washington
Phone: 509-456-8444